Precision Omics for the Next Generation of Biotech

Omix Technologies pioneers ultra high-throughput mass spectrometry workflows for quantitative proteomics and metabolomics, delivering industry-leading accuracy, precision, and scalability. Our 96-well platform enables population-scale omics profiling—generating deep molecular datasets that uncover insights into human biology, disease risk, and therapeutic potential. These capabilities power advancements across molecular epidemiology, omics-guided drug screening, innovative solutions for blood systems management, and regenerative medicine—where detailed molecular characterization informs organ bioengineering, extracellular matrix design, and next-generation cell therapies. 

Blood Products

From transfusion medicine (e.g., red blood cell and platelet storage) to blood farming to the role of blood cells and blood-derived therapeutics in health and disease, we provide cutting edge technologies for the design and development of novel blood storage strategies and blood-based therapeutic interventions. Read more here.

Regenerative Medicine

From organ regeneration to stem cell expansion for clinical application, our technology provides qualitative and quantitative characterization of the organ extracellular matrix to inform development and quality control of next generation biomedical products for regenerative medicine. Read more here.

Personalized Medicine

Proteomics and metabolomics are closer to the phenotype than genomics and transcriptomics, the latter of which have been heavily utilized for recent advancements in Personalized Medicine. As we expand our understanding of the roles that biological variability and environmental factors play in health and disease, our high-throughput approaches make it feasible to apply next-gen Omix to clinical workflows thus providing clues for the development and repurposing of pharmaceutical products. Read more here.